Incyte Streamlines Pipeline After Difficult Q1
Company Still Looking For Jakafi Combination
Executive Summary
The mid-sized pharma company has a blockbuster in Jakafi, but analysts are doubtful about its plans to build on that base across its now slimmed-down pipeline.
You may also be interested in...
Incyte Enters A Data-Rich Year On Path To Portfolio Diversification
Incyte’s Jakafi-dominated portfolio gained Opzelura as a second source of significant revenue in 2021. While further diversification has been limited, new and existing R&D assets may deliver upside in 2024.
Long-Term Vitiligo Data Appear To Lay Opzelura Safety Concerns To Rest
Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.
Incyte Pulls Parsaclisib Files As FDA Takes Foot Off Accelerator
After discussions with the FDA, which has made its feelings clear on accelerated approvals, Incyte has concluded it cannot complete the confirmatory trials in lymphomas that would be needed on parsaclisib in time to make them worth their while.